October 9, 2014, NBT and REMD Biotherapeutics, a US biotech company, signed a collaboration contract on ADC drug development. NBT will use its site-specific linkers and proprietary payload to develop ADCs as potential therapeutics for the treatments of colorectal cancer and lung cancers.